X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
VX-147 (inaxaplin) is an oral, small-molecule inhibitor of APOL1 channel function, which is being evaluated for the treatment of APOL1-mediated kidney disease.
Lead Product(s): Inaxaplin
Therapeutic Area: Nephrology Product Name: VX-147
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
(VX-147) inaxaplin is an orally active APOL1 inhibitor aimed at treating the underlying cause of focal segmental glomerulosclerosis (FSGS) and APOL1-mediated kidney disease (AMKD).
Lead Product(s): Inaxaplin
Therapeutic Area: Nephrology Product Name: VX-147
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
The primary efficacy endpoint for the final analysis is eGFR slope in patients receiving the VX-147 (inaxaplin) selected dose compared to placebo. The secondary efficacy endpoint is time to composite clinical outcome.
Lead Product(s): Inaxaplin
Therapeutic Area: Nephrology Product Name: VX-147
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
